ArticleInternational journal of peptides2012
Leptin in anorexia and cachexia syndrome.
Article in International journal of peptides, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Association between body mass index at different levels and risk of gastroesophageal reflux disease: a systematic review with dose-response meta-analysis.Frontiers in physiology · 2025Pooled it
- Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2015Trial
- BMI and PNI as predictors of treatment completion and survival in locally advanced HNSCC receiving sequential chemoradiotherapy.BMC cancer · 2025Article
- Review
- Exploring the potential of ginseng-derived compounds in treating cancer cachexia.Journal of ginseng research · 2025Review
- Metabolic underpinnings of cancer-related fatigue.American journal of physiology. Endocrinology and metabolism · 2024Review
- A Review of Olanzapine in the Treatment of Cancer Anorexia-Cachexia Syndrome.Pharmacy (Basel, Switzerland) · 2024Review
- Nutrition and Dietary Intervention in Cancer: Gaps, Challenges, and Future Perspectives.Cancer treatment and research · 2024Review
- Cancer-triggered systemic disease and therapeutic targets.Holistic integrative oncology · 2024Article
- THE PREDICTIVE ROLE OF LEPTIN IN MALNUTRITION-INFLAMMATION COMPLEX SYNDROME IN HEMODIALYSIS PATIENTS.Acta clinica Croatica · 2023Article
- Review
- Association between Leptin (G2548A) and Leptin Receptor (Q223R) Polymorphisms with Plasma Leptin, BMI, Stress, Sleep and Eating Patterns among the Multiethnic Young Malaysian Adult Population from a Healthcare University.International journal of environmental research and public health · 2022Article
- Understanding the molecular basis of anorexia and tissue wasting in cancer cachexia.Experimental & molecular medicine · 2022Review
- Cancer cachexia as a multiorgan failure: Reconstruction of the crime scene.Frontiers in cell and developmental biology · 2022Review
- Article
- Asprosin is associated with anorexia and body fat mass in cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Review
- Nonclassical Islet Peptides: Pancreatic and Extrapancreatic Actions.Clinical medicine insights. Endocrinology and diabetes · 2019Review
- Leptin and ghrelin in chronic kidney disease: their associations with protein-energy wasting.Pediatric nephrology (Berlin, Germany) · 2018Article
- Cancer anorexia: hypothalamic activity and its association with inflammation and appetite-regulating peptides in lung cancer.Journal of cachexia, sarcopenia and muscle · 2017Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Leptin is a product of the obese (OB) gene secreted by adipocytes in proportion to fat mass. It decreases food intake and increases energy expenditure by affecting the balance between orexigenic and anorexigenic hypothalamic pathways. Low leptin levels are responsible for the compensatory increase in appetite and body weight and decreased energy expenditure (EE) following caloric deprivation. The anorexia-cachexia syndrome is a complication of many chronic conditions including cancer, chronic obstructive pulmonary disease, congestive heart failure, chronic kidney disease, and aging, where the decrease in body weight and food intake is not followed by a compensatory increase in appetite or decreased EE. Crosstalk between leptin and inflammatory signaling known to be activated in these conditions may be responsible for this paradox. This manuscript will review the evidence and potential mechanisms mediating changes in the leptin pathway in the setting of anorexia and cachexia associated with chronic diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.